FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

MS Patients Seen to Safely Switch to Oral Drugs from Injectable Oral Therapies


























By Magdalena Kegel

Stable multiple sclerosis (MS) patients do not appear to be at any increased risk of disease reactivation while switching to oral therapy following treatment with injectable interferon-β/glatiramer acetate (IFNβ/GA), a study reports.

Recently published in the European Journal of Neurology, the Australian study was titled “Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.“

Earlier research had raised concerns that people switching to the oral immunomodulating drug fingolimod (Gilenya) could be at increased risk of MS relapse, but little data has been collected on the six-month period following a switch in treatments.

The research team from the Royal Melbourne Hospital compared 396 MS patients moving from IFNβ/GA to oral drugs to an equal number of MS patients who remained on the injectable treatment. The study analyzed data from patients who had been stable on the IFNβ/GA treatment for at least the previous 12 months.

The team analyzed the frequency of relapse and disability progression, and found no differences between the two groups, either in the rate of relapse or in disease progression. Relapses in both groups were relatively rare, with 7.3 percent of the switchers experiencing a relapse, compared to 6.6 percent of patients remaining on injectable treatment.

Researchers also analyzed patients divided into subgroups based on the type of oral treatment given. Most switched to fingolimod (71.2 percent), but 16.2 percent moved to dimethyl fumarate, and the remaining to teriflunomide. Again, the researchers could not detect any differences in relapse rate among patients in these three groups. The time of washout of IFNβ/GA treatment also was not linked to an increased relapse risk or disease progression.

Injectable MS drugs are associated with a range of problems, including poor treatment adherence due to side effects, which can increase the risk of relapse. Oral treatment options now available may better serve this population. The study concluded that switching to oral therapy was not associated with any negative outcomes during the six months following a treatment switch in stable patients. Nevertheless, more research is needed to evaluate long-term effects.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length



Go to Newer News Go to Older News